HX630 is a synthetic RXR pan-agonist. HX-630 has bein shown to exert anti-proliferative and pro-apoptotic effects in murine pituitary corticotroph tumor AtT20 cells, making HX-630 a new therapeutic candidate for Cushing’s disease. It might also serve as potential pharmacological tool for treating retina degenerative diseases and Alzheimer's disease.

(+)-Rotigotine is the inactive enantiomer of dopamine receptor agonist (-)-Rotigotine. (+)-Rotigotine is weak agonist of dopamine receptor.

T0901317 is a potent, high affinity liver X receptors (LXRs) agonist. It upregulates expression of the ABCA1 gene associated with cholesterol efflux regulation and high-density lipoproteins metabolism. It also exhibits inverse agonist activity at constitutive androstane receptors (CARs). T0901317 activates bile acid farnesoid X receptors (FXRs), and it is 10-fold more potent than natural FXR ligand chenodeoxycholic acid.

Adenosine 2'-monophosphate (2’-AMP) is adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'- position. Exogenous 2’-AMP is rapidly converted to adenosine in vitro and in vivo. In vitro 2’-AMP alter vascular smooth muscle cell, endothelial cell, and epithelial cell proliferation via adenosine receptors activation. In vitro 2’-AMP dose-dependently and profoundly reduce mean arterial blood pressure, heart rate, total peripheral (TPR), mesenteric vascular (MVR) resistances with efficacies and potencies equal to or greater than those for adenosine. Adenosine 2'-monophosphate has been used in the synthesis of a novel photoaffinity label for the coenzyme site of porcine NADP-specific isocitrate dehydrogenase. Adenosine 2'-monophosphate also can be used as a tool for studying adenosine-based cell regulation.

8-Hyroxy-2-Dipropylaminotetralin Hydrobromide (8-OH-DPAT) is a chemical predominantly used in research settings. It is widely regarded as the first identified complete agonist of the 5-HT1a receptor, for which it has a Ki = 3.18 nM. 8-OH-DPAT also acts as an agonist of the 5-HT7 receptor, and as a substrate of the Sodium dependent serotonin transporter (SERT). Although it has never progressed to human clinical trials 8-OH-DPAT has been studied in animal models for a number of conditions both for its own potential and as a benchmark for other compounds.